Prifinium is an antimuscarinic agent with antispasmodic and antiemetic properties. It may be useful for the treatment of irritable bowel syndrome A175027.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Aclidinium | The risk or severity of adverse effects can be increased when Prifinium is combined with Aclidinium. |
| Mianserin | Mianserin may increase the anticholinergic activities of Prifinium. |
| Mirabegron | The risk or severity of urinary retention can be increased when Prifinium is combined with Mirabegron. |
| Pramlintide | The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Prifinium. |
| Secretin porcine | The therapeutic efficacy of Secretin porcine can be decreased when used in combination with Prifinium. |
| Tiotropium | The risk or severity of adverse effects can be increased when Prifinium is combined with Tiotropium. |
| Topiramate | The risk or severity of hyperthermia and oligohydrosis can be increased when Prifinium is combined with Topiramate. |
| Umeclidinium | The risk or severity of adverse effects can be increased when Prifinium is combined with Umeclidinium. |
| Glycopyrronium | The risk or severity of adverse effects can be increased when Prifinium is combined with Glycopyrronium. |
| Botulinum toxin type A | The risk or severity of adverse effects can be increased when Prifinium is combined with Botulinum toxin type A. |
| Glucagon | Prifinium may increase the gastrointestinal motility reducing activities of Glucagon. |
| Sulpiride | Prifinium may increase the anticholinergic activities of Sulpiride. |
| Botulinum toxin type B | The risk or severity of adverse effects can be increased when Prifinium is combined with Botulinum toxin type B. |
| Eluxadoline | The risk or severity of constipation can be increased when Prifinium is combined with Eluxadoline. |
| Ramosetron | The risk or severity of constipation can be increased when Prifinium is combined with Ramosetron. |
| Naltrexone | The risk or severity of adverse effects can be increased when Prifinium is combined with Naltrexone. |
| Bezitramide | The risk or severity of adverse effects can be increased when Prifinium is combined with Bezitramide. |
| Tramadol | The risk or severity of adverse effects can be increased when Prifinium is combined with Tramadol. |
| Morphine | The risk or severity of adverse effects can be increased when Prifinium is combined with Morphine. |
| Codeine | The risk or severity of adverse effects can be increased when Prifinium is combined with Codeine. |
| Hydromorphone | The risk or severity of adverse effects can be increased when Prifinium is combined with Hydromorphone. |
| Methadone | The risk or severity of adverse effects can be increased when Prifinium is combined with Methadone. |
| Meperidine | The risk or severity of adverse effects can be increased when Prifinium is combined with Meperidine. |
| Oxycodone | The risk or severity of adverse effects can be increased when Prifinium is combined with Oxycodone. |
| Butorphanol | The risk or severity of adverse effects can be increased when Prifinium is combined with Butorphanol. |
| Dextropropoxyphene | The risk or severity of adverse effects can be increased when Prifinium is combined with Dextropropoxyphene. |
| Pentazocine | The risk or severity of adverse effects can be increased when Prifinium is combined with Pentazocine. |
| Sufentanil | The risk or severity of adverse effects can be increased when Prifinium is combined with Sufentanil. |
| Alfentanil | The risk or severity of adverse effects can be increased when Prifinium is combined with Alfentanil. |
| Fentanyl | The risk or severity of adverse effects can be increased when Prifinium is combined with Fentanyl. |
| Nalbuphine | The risk or severity of adverse effects can be increased when Prifinium is combined with Nalbuphine. |
| Levorphanol | The risk or severity of adverse effects can be increased when Prifinium is combined with Levorphanol. |
| Remifentanil | The risk or severity of adverse effects can be increased when Prifinium is combined with Remifentanil. |
| Buprenorphine | The risk or severity of adverse effects can be increased when Prifinium is combined with Buprenorphine. |
| Hydrocodone | The risk or severity of adverse effects can be increased when Prifinium is combined with Hydrocodone. |
| Diphenoxylate | The risk or severity of adverse effects can be increased when Prifinium is combined with Diphenoxylate. |
| Oxymorphone | The risk or severity of adverse effects can be increased when Prifinium is combined with Oxymorphone. |
| Dezocine | The risk or severity of adverse effects can be increased when Prifinium is combined with Dezocine. |
| Levacetylmethadol | The risk or severity of adverse effects can be increased when Prifinium is combined with Levacetylmethadol. |
| Methadyl acetate | The risk or severity of adverse effects can be increased when Prifinium is combined with Methadyl acetate. |
| Dihydroetorphine | The risk or severity of adverse effects can be increased when Prifinium is combined with Dihydroetorphine. |
| Diamorphine | The risk or severity of adverse effects can be increased when Prifinium is combined with Diamorphine. |
| Ethylmorphine | The risk or severity of adverse effects can be increased when Prifinium is combined with Ethylmorphine. |
| Etorphine | The risk or severity of adverse effects can be increased when Prifinium is combined with Etorphine. |
| Dextromoramide | The risk or severity of adverse effects can be increased when Prifinium is combined with Dextromoramide. |
| Desomorphine | The risk or severity of adverse effects can be increased when Prifinium is combined with Desomorphine. |
| Carfentanil | The risk or severity of adverse effects can be increased when Prifinium is combined with Carfentanil. |
| Dihydrocodeine | The risk or severity of adverse effects can be increased when Prifinium is combined with Dihydrocodeine. |
| Alphacetylmethadol | The risk or severity of adverse effects can be increased when Prifinium is combined with Alphacetylmethadol. |
| Dihydromorphine | The risk or severity of adverse effects can be increased when Prifinium is combined with Dihydromorphine. |
| Tapentadol | The risk or severity of urinary retention and constipation can be increased when Prifinium is combined with Tapentadol. |
| Ketobemidone | The risk or severity of adverse effects can be increased when Prifinium is combined with Ketobemidone. |
| DPDPE | The risk or severity of adverse effects can be increased when Prifinium is combined with DPDPE. |
| Lofentanil | The risk or severity of adverse effects can be increased when Prifinium is combined with Lofentanil. |
| Opium | The risk or severity of adverse effects can be increased when Prifinium is combined with Opium. |
| Normethadone | The risk or severity of adverse effects can be increased when Prifinium is combined with Normethadone. |
| Piritramide | The risk or severity of adverse effects can be increased when Prifinium is combined with Piritramide. |
| Alphaprodine | The risk or severity of adverse effects can be increased when Prifinium is combined with Alphaprodine. |
| Nicomorphine | The risk or severity of adverse effects can be increased when Prifinium is combined with Nicomorphine. |
| Meptazinol | The risk or severity of adverse effects can be increased when Prifinium is combined with Meptazinol. |
| Phenoperidine | The risk or severity of adverse effects can be increased when Prifinium is combined with Phenoperidine. |
| Phenazocine | The risk or severity of adverse effects can be increased when Prifinium is combined with Phenazocine. |
| Tilidine | The risk or severity of adverse effects can be increased when Prifinium is combined with Tilidine. |
| Carfentanil, C-11 | The risk or severity of adverse effects can be increased when Prifinium is combined with Carfentanil, C-11. |
| Benzhydrocodone | The risk or severity of adverse effects can be increased when Prifinium is combined with Benzhydrocodone. |
| Naloxegol | The risk or severity of adverse effects can be increased when Prifinium is combined with Naloxegol. |
| Trospium | The risk or severity of adverse effects can be increased when Trospium is combined with Prifinium. |
| Oxyphenonium | The risk or severity of adverse effects can be increased when Oxyphenonium is combined with Prifinium. |
| Benzatropine | The risk or severity of adverse effects can be increased when Benzatropine is combined with Prifinium. |
| Disopyramide | The risk or severity of adverse effects can be increased when Disopyramide is combined with Prifinium. |
| Metixene | The risk or severity of adverse effects can be increased when Metixene is combined with Prifinium. |
| Terfenadine | The risk or severity of adverse effects can be increased when Terfenadine is combined with Prifinium. |
| Buclizine | The risk or severity of adverse effects can be increased when Buclizine is combined with Prifinium. |
| Trihexyphenidyl | The risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Prifinium. |
| Oxyphencyclimine | The risk or severity of adverse effects can be increased when Oxyphencyclimine is combined with Prifinium. |
| Procyclidine | The risk or severity of adverse effects can be increased when Procyclidine is combined with Prifinium. |
| Hyoscyamine | The risk or severity of adverse effects can be increased when Hyoscyamine is combined with Prifinium. |
| Methscopolamine bromide | The risk or severity of adverse effects can be increased when Methscopolamine bromide is combined with Prifinium. |
| Darifenacin | The risk or severity of adverse effects can be increased when Darifenacin is combined with Prifinium. |
| Tridihexethyl | The risk or severity of adverse effects can be increased when Tridihexethyl is combined with Prifinium. |
| Anisotropine methylbromide | The risk or severity of adverse effects can be increased when Anisotropine methylbromide is combined with Prifinium. |
| Atropine | The risk or severity of adverse effects can be increased when Atropine is combined with Prifinium. |
| Nicardipine | The risk or severity of adverse effects can be increased when Nicardipine is combined with Prifinium. |
| Mecamylamine | The risk or severity of adverse effects can be increased when Mecamylamine is combined with Prifinium. |
| Pirenzepine | The risk or severity of adverse effects can be increased when Pirenzepine is combined with Prifinium. |
| Homatropine methylbromide | The risk or severity of adverse effects can be increased when Homatropine methylbromide is combined with Prifinium. |
| Benzquinamide | The risk or severity of adverse effects can be increased when Benzquinamide is combined with Prifinium. |
| Propantheline | The risk or severity of adverse effects can be increased when Propantheline is combined with Prifinium. |
| Dicyclomine | The risk or severity of adverse effects can be increased when Dicyclomine is combined with Prifinium. |
| Tropicamide | The risk or severity of adverse effects can be increased when Tropicamide is combined with Prifinium. |
| Cocaine | The risk or severity of adverse effects can be increased when Cocaine is combined with Prifinium. |
| Quinidine | The risk or severity of adverse effects can be increased when Quinidine is combined with Prifinium. |
| Amantadine | The risk or severity of adverse effects can be increased when Amantadine is combined with Prifinium. |
| Methantheline | The risk or severity of adverse effects can be increased when Methantheline is combined with Prifinium. |
| Cycrimine | The risk or severity of adverse effects can be increased when Cycrimine is combined with Prifinium. |
| Cyclopentolate | The risk or severity of adverse effects can be increased when Cyclopentolate is combined with Prifinium. |
| Tolterodine | The risk or severity of adverse effects can be increased when Tolterodine is combined with Prifinium. |
| Oxybutynin | The risk or severity of adverse effects can be increased when Oxybutynin is combined with Prifinium. |
| Pentolinium | The risk or severity of adverse effects can be increased when Pentolinium is combined with Prifinium. |
| Trimethaphan | The risk or severity of adverse effects can be increased when Trimethaphan is combined with Prifinium. |